Silence Therapeutics (LON:SLN) had its price objective boosted by Peel Hunt from GBX 276 ($3.81) to GBX 277 ($3.83) in a report issued on Tuesday morning. Peel Hunt currently has a buy rating on the stock.
Shares of Silence Therapeutics (LON SLN) opened at GBX 195 ($2.69) on Tuesday. Silence Therapeutics has a 1 year low of GBX 71.88 ($0.99) and a 1 year high of GBX 254.75 ($3.52). The firm has a market cap of $135.55 and a P/E ratio of -9,750.00.
Silence Therapeutics (LON:SLN) last released its quarterly earnings results on Tuesday, March 6th. The company reported GBX (2.30) (($0.03)) earnings per share for the quarter. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%. The company had revenue of GBX 2 million for the quarter.
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.